Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749886 | 0.89 | CYP1A2 (0.36) | CYP1A2CYP2D6EPHX1 | |
| SCHEMBL1104692 | 0.82 | — | — | |
| SCHEMBL1104700 | 0.82 | — | — | |
| SCHEMBL804429 | 0.82 | — | — | |
| SCHEMBL26940299 | 0.82 | CYP1A2 (0.38) | CYP1A2CYP2D6EPHX1 | |
| SCHEMBL16689109 | 0.81 | PIK3CD (0.30) | PIK3CD | |
| SCHEMBL26513234 | 0.78 | EPHX1 (0.40) | CYP1A2CYP2D6EPHX1 | |
| SCHEMBL22570229 | 0.78 | EPHX1 (0.40) | CYP1A2CYP2D6EPHX1 | |
| SCHEMBL24310239 | 0.77 | — | — | |
| SCHEMBL55948 | 0.77 | ALDH1A1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1673 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | ARTUS THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-12024500-B2 | Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
| US-7244735-B2 | Heterocyclic protein kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-7227035-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX (US) | 2007-06-05 | — | — | US | disclosed |
| US-7202247-B2 | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | ATHEROGENICS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202247-B2 | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | ATHEROGENICS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070043023-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043023-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024500-B2 | Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof | DDT, CYP3A5, CYP4B1 | CYP1A2 15/4885CYP2D6 37/4885EPHX1 255/4885 |
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | CYP1A2 3232/4885CYP2D6 4042/4885EPHX1 4067/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CYP1A2 603/4885CYP2D6 993/4885EPHX1 1130/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | CYP1A2 4854/4885CYP2D6 4827/4885EPHX1 2619/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | CYP1A2 2006/4885CYP2D6 1631/4885EPHX1 1840/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | CYP1A2 1645/4885CYP2D6 2650/4885EPHX1 1074/4885 |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | LIPG, FABP2, EPCAM | CYP1A2 4754/4885CYP2D6 4869/4885EPHX1 256/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | CYP1A2 973/4885CYP2D6 865/4885EPHX1 4478/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | CYP1A2 391/4885CYP2D6 608/4885EPHX1 1463/4885 |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | CYP1A2 3456/4885CYP2D6 3877/4885EPHX1 1924/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CYP1A2 50/4885CYP2D6 33/4885EPHX1 778/4885 |
| US-20070043023-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | CYP1A2 1140/4885CYP2D6 1646/4885EPHX1 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.